SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-23-003545
Filing Date
2023-03-17
Accepted
2023-03-17 08:06:43
Documents
15
Period of Report
2023-03-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_031622.htm   iXBRL 8-K 40979
2 TRANSCRIPT OF CONFERENCE CALL ex99-1.htm EX-99.1 46627
3 TRANSCRIPT OF VIDEO PRESENTATION ex99-2.htm EX-99.2 19211
4 PRESS RELEASE ex99-3.htm EX-99.3 42984
  Complete submission text file 0001387131-23-003545.txt   361334

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE admp-20230316.xsd EX-101.SCH 3266
6 XBRL LABEL FILE admp-20230316_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE admp-20230316_pre.xml EX-101.PRE 22385
9 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_031622_htm.xml XML 3588
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 23740727
SIC: 2834 Pharmaceutical Preparations